Ikarian-Capital

Filing Details

13F-HR2025-03-31
Report Date
2025-03-31
Filing Date
2025-05-15
Total Holdings
141
Total Value
710178588
Accession Number
0001420506-25-001276
Form Type
13F-HR
Manager Name
Ikarian-Capital
Data Enrichment
96% identified
135 identified6 unidentified

Holdings

141 positions
Manager:
Search and click to pin securities to the top
Page 4 of 8
Oruka Therapeutics, Inc.
Shares:175.0K
Value:$1.8M
Apellis Pharmaceuticals, Inc.
Shares:75.0K
Value:$1.6M
Verve Therapeutics, Inc.
Shares:358.4K
Value:$1.6M
ARVINAS, INC.
Shares:229.9K
Value:$1.6M
Avalo Therapeutics, Inc.
Shares:200.0K
Value:$1.6M
Arcturus Therapeutics Holdings Inc.
Shares:150.0K
Value:$1.6M
HARROW, INC.
Shares:58.3K
Value:$1.6M
Vistagen Therapeutics, Inc.
Shares:601.7K
Value:$1.5M
ROCKET PHARMACEUTICALS, INC.
Shares:221.9K
Value:$1.5M
Ventyx Biosciences, Inc.
Shares:1.2M
Value:$1.4M
Arcus Biosciences, Inc.
Shares:163.4K
Value:$1.3M
DELCATH SYSTEMS, INC.
Shares:100.4K
Value:$1.3M
Compass Therapeutics, Inc.
Shares:662.2K
Value:$1.3M
PROTHENA CORP PUBLIC LTD CO
Shares:100.0K
Value:$1.2M
SANGAMO THERAPEUTICS, INC
Shares:1.9M
Value:$1.2M
Altimmune, Inc.
Shares:240.0K
Value:$1.2M
Teladoc Health, Inc.
Shares:150.0K
Value:$1.2M
Alector, Inc.
Shares:950.0K
Value:$1.2M
OnKure Therapeutics, Inc.
Shares:253.8K
Value:$1.1M
Nuvation Bio Inc.
Shares:619.3K
Value:$1.1M